{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:44:57Z","timestamp":1791571497425,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>Polycystic Ovary Syndrome (PCOS) affects 10\u201315% of women of reproductive age and is associated with a heightened risk of metabolic morbidity, exacerbated by insulin resistance and obesity. Current weight management strategies have limited effectiveness in reducing metabolic morbidity in this subgroup. This review examines the potential of Intensive Weight Management Programmes (IWMPs) and Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to reduce metabolic risks in women with PCOS, drawing from studies in both PCOS-specific and related populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>IWMPs, including total diet replacement, achieve substantial and sustained weight loss (5\u201315% over 1\u20135 years) in individuals with obesity and type 2 diabetes, alongside improvements in metabolic markers like blood pressure and glycemic control. GLP-1 RAs, particularly semaglutide, similarly deliver significant weight loss (10\u201315% over 1\u20132 years) and metabolic benefits. While there is limited data specifically targeting PCOS, emerging studies suggest GLP-1 RAs can improve weight, insulin sensitivity, and menstrual regularity in this group. However, evidence for both interventions in PCOS remains insufficient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Women with PCOS face unique metabolic challenges, including heightened insulin resistance, compounded by obesity. While IWMPs and GLP-1 RAs are promising interventions, evidence for their effectiveness in PCOS-specific populations is insufficient. Addressing this research gap through targeted trials is essential to improve outcomes in individuals affected by PCOS and metabolic disorders.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s13679-025-00614-2","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:36:11Z","timestamp":1741221371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1104-7739","authenticated-orcid":false,"given":"Michail","family":"Diakosavvas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0925-9839","authenticated-orcid":false,"given":"Oyinlola","family":"Oyebode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0871-6508","authenticated-orcid":false,"given":"Priya","family":"Bhide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"614_CR1","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","volume":"108","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international Evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108:2447\u201369. https:\/\/doi.org\/10.1210\/clinem\/dgad463.","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/humupd\/dmp008","volume":"15","author":"L Moran","year":"2009","unstructured":"Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15:477\u201388. https:\/\/doi.org\/10.1093\/humupd\/dmp008.","journal-title":"Hum Reprod Update"},{"key":"614_CR3","doi-asserted-by":"publisher","first-page":"741764","DOI":"10.3389\/fendo.2021.741764","volume":"12","author":"H Ding","year":"2021","unstructured":"Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, et al. Resistance to the insulin and elevated level of Androgen: A major cause of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2021;12:741764. https:\/\/doi.org\/10.3389\/fendo.2021.741764.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"614_CR4","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1038\/s41598-024-53229-3","volume":"14","author":"F Chen","year":"2024","unstructured":"Chen F, Shi Y, Yu M, Hu Y, Li T, Cheng Y, et al. Joint effect of BMI and metabolic status on mortality among adults: A population-based longitudinal study in united States. Sci Rep. 2024;14:2775. https:\/\/doi.org\/10.1038\/s41598-024-53229-3.","journal-title":"Sci Rep"},{"key":"614_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1530\/EJE-21-0669","volume":"186","author":"A Dietz de Loos","year":"2021","unstructured":"Dietz de Loos A, Jiskoot G, Beerthuizen A, Busschbach J, Laven J. Metabolic health during a randomized controlled lifestyle intervention in women with PCOS. Eur J Endocrinol. 2021;186:53\u201364. https:\/\/doi.org\/10.1530\/EJE-21-0669.","journal-title":"Eur J Endocrinol"},{"key":"614_CR6","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/s41366-021-00915-1","volume":"45","author":"NM Astbury","year":"2021","unstructured":"Astbury NM, Edwards RM, Ghebretinsea F, Shanyinde M, Mollison J, Aveyard P, et al. Extended follow-up of a short total diet replacement programme: results of the Doctor referral of overweight people to low energy total diet replacement treatment (DROPLET) randomized controlled trial at 3 years. Int J Obes (Lond). 2021;45:2432\u20138. https:\/\/doi.org\/10.1038\/s41366-021-00915-1.","journal-title":"Int J Obes (Lond)"},{"key":"614_CR7","doi-asserted-by":"publisher","first-page":"3609642","DOI":"10.1155\/2019\/3609642","volume":"2019","author":"JL Kuk","year":"2019","unstructured":"Kuk JL, Christensen RAG, Wharton S. Absolute weight loss, and not weight loss rate, is associated with better improvements in metabolic health. J Obes. 2019;2019:3609642. https:\/\/doi.org\/10.1155\/2019\/3609642.","journal-title":"J Obes"},{"key":"614_CR8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1161\/01.HYP.0000165680.59733.d4","volume":"45","author":"L Aucott","year":"2005","unstructured":"Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight\/obese individuals and long-term hypertension outcomes: A systematic review. Hypertension. 2005;45:1035\u201341. https:\/\/doi.org\/10.1161\/01.HYP.0000165680.59733.d4.","journal-title":"Hypertension"},{"key":"614_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1467-789X.2004.00127.x","volume":"5","author":"A Poobalan","year":"2004","unstructured":"Poobalan A, Aucott L, Smith WC, Avenell A, Jung R, Broom J, et al. Effects of weight loss in overweight\/obese individuals and long-term lipid outcomes: A systematic review. Obes Rev. 2004;5:43\u201350. https:\/\/doi.org\/10.1111\/j.1467-789X.2004.00127.x.","journal-title":"Obes Rev"},{"key":"614_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or Metformin. N Engl J Med. 2002;346:393\u2013403. https:\/\/doi.org\/10.1056\/NEJMoa012512.","journal-title":"N Engl J Med"},{"key":"614_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/aogs.14725","volume":"103","author":"M Forslund","year":"2024","unstructured":"Forslund M, Melin J, Stener-Victorin E, Hirschberg AL, Teede H, Vanky E, et al. International evidence\u2010based guideline on assessment and management of PCOS \u2014 A nordic perspective. Acta Obstet Gynecol Scand. 2024;103:7\u201312. https:\/\/doi.org\/10.1111\/aogs.14725.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"614_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","volume":"120","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international Evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120:767\u201393. https:\/\/doi.org\/10.1016\/j.fertnstert.2023.07.025.","journal-title":"Fertil Steril"},{"key":"614_CR13","doi-asserted-by":"publisher","unstructured":"Engmann L, Jin S, Sun F, Legro RS, Polotsky AJ, Hansen KR, et al. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. Am J Obstet Gynecol. 2017;216. https:\/\/doi.org\/10.1016\/j.ajog.2017.01.003.:493.e1-493.e13.","DOI":"10.1016\/j.ajog.2017.01.003"},{"key":"614_CR14","doi-asserted-by":"publisher","unstructured":"Yeo JL, Brady EM, McCann GP, Gulsin GS. Sex and ethnic differences in the cardiovascular complications of type 2 diabetes. Ther Adv Endocrinol Metab. 2021;12. https:\/\/doi.org\/10.1177\/20420188211034297.","DOI":"10.1177\/20420188211034297"},{"key":"614_CR15","unstructured":"Public Health England. National mapping of weight management services. 2015 https:\/\/assets.publishing.service.gov.uk\/media\/5a7f74d2e5274a2e8ab4c4b1\/Final_Weight_Management_Mapping_Report.pdf"},{"key":"614_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3310\/nihropenres.13233.4","volume":"1","author":"G Farhat","year":"2021","unstructured":"Farhat G, Majeed S, Rutter MK, Issa B, Harvie M. Comparing the acceptability of total diet replacement and food-based low energy diets for type 2 diabetes remission amongst South Asians: A public and patient involvement activity. NIHR Open Res. 2021;1:24. https:\/\/doi.org\/10.3310\/nihropenres.13233.4.","journal-title":"NIHR Open Res"},{"key":"614_CR17","unstructured":"Khunti K, Kumar S, Brodie J, Diabetes, UK and South Asian Health Foundation recommendations on diabetes research priorities for British South Asians. 2009 https:\/\/www.diabetes.org.uk\/resources-s3\/2017-11\/south_asian_report.pdf"},{"key":"614_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"ME Lean","year":"2018","unstructured":"Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomized trial. Lancet. 2018;391:541\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(17)33102-1.","journal-title":"Lancet"},{"key":"614_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","volume":"7","author":"MEJ Lean","year":"2019","unstructured":"Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the direct open-label, cluster-randomized trial. Lancet Diabetes Endocrinol. 2019;7:344\u201355. https:\/\/doi.org\/10.1016\/S2213-8587(19)30068-3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"614_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(23)00385-6","volume":"12","author":"ME Lean","year":"2024","unstructured":"Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. 5-year follow-up of the randomized diabetes remission clinical trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12:233\u201346. https:\/\/doi.org\/10.1016\/S2213-8587(23)00385-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"614_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fnut.2018.00054","volume":"5","author":"R Golubic","year":"2018","unstructured":"Golubic R, Laur C, Kelsey M, Livesy A, Hoensch J, Park A, et al. The Cambridge intensive weight management programme appears to promote weight loss and reduce the need for bariatric surgery in obese adults. Front Nutr. 2018;5:54. https:\/\/doi.org\/10.3389\/fnut.2018.00054.","journal-title":"Front Nutr"},{"key":"614_CR22","doi-asserted-by":"publisher","first-page":"k3760","DOI":"10.1136\/bmj.k3760","volume":"362","author":"NM Astbury","year":"2018","unstructured":"Astbury NM, Aveyard P, Nickless A, Hood K, Corfield K, Lowe R, et al. Doctor referral of overweight people to low energy total diet replacement treatment (DROPLET): pragmatic randomized controlled trial. BMJ. 2018;362:k3760. https:\/\/doi.org\/10.1136\/bmj.k3760.","journal-title":"BMJ"},{"key":"614_CR23","doi-asserted-by":"publisher","first-page":"551068","DOI":"10.3389\/fnut.2020.551068","volume":"7","author":"R Abdalgwad","year":"2020","unstructured":"Abdalgwad R, Rafey MF, Foy S, Newell M, Davenport C, O\u2019Keeffe DT, et al. Long-Term changes in weight in patients with severe and complicated obesity after completion of a Milk-Based meal replacement programme. Front Nutr. 2020;7:551068. https:\/\/doi.org\/10.3389\/fnut.2020.551068.","journal-title":"Front Nutr"},{"key":"614_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2147\/DMSO.S226327","volume":"13","author":"MF Rafey","year":"2020","unstructured":"Rafey MF, Murphy CF, Abdalgwad R, Kilkelly K, Griffin H, Beatty N, et al. Effects of a Milk-Based meal replacement program on weight and metabolic characteristics in adults with severe obesity. Diabetes Metab Syndr Obes. 2020;13:197\u2013205. https:\/\/doi.org\/10.2147\/DMSO.S226327.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"614_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2337\/dc23-0781","volume":"47","author":"SL Hocking","year":"2024","unstructured":"Hocking SL, Markovic TP, Lee CMY, Picone TJ, Gudorf KE, Colagiuri S. Intensive lifestyle intervention for remission of early type 2 diabetes in primary care in Australia: DiRECT-Aus. Diabetes Care. 2024;47:66\u201370. https:\/\/doi.org\/10.2337\/dc23-0781.","journal-title":"Diabetes Care"},{"key":"614_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13063-018-2660-1","volume":"19","author":"S Taheri","year":"2018","unstructured":"Taheri S, Chagoury O, Zaghloul H, Elhadad S, Ahmed SH, Omar O, et al. Diabetes intervention accentuating diet and enhancing metabolism (DIADEM-I): a randomised controlled trial to examine the impact of an intensive lifestyle intervention consisting of a low-energy diet and physical activity on body weight and metabolism in early type 2 diabetes mellitus: study protocol for a randomized controlled trial. Trials. 2018;19:284. https:\/\/doi.org\/10.1186\/s13063-018-2660-1.","journal-title":"Trials"},{"key":"614_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S2213-8587(20)30117-0","volume":"8","author":"S Taheri","year":"2020","unstructured":"Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH, El Khatib N, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8:477\u201389. https:\/\/doi.org\/10.1016\/S2213-8587(20)30117-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"614_CR28","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.lansea.2022.100111","volume":"9","author":"N Sattar","year":"2023","unstructured":"Sattar N, Welsh P, Leslie WS, Thom G, McCombie L, Brosnahan N, et al. Dietary weight-management for type 2 diabetes remissions in South Asians: the South Asian diabetes remission randomised trial for proof-of-concept and feasibility (STANDby). Lancet Reg Health Southeast Asia. 2023;9:100111. https:\/\/doi.org\/10.1016\/j.lansea.2022.100111.","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"614_CR29","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsb\u00f8ll","year":"2012","unstructured":"Vilsb\u00f8ll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. https:\/\/doi.org\/10.1136\/bmj.d7771.","journal-title":"BMJ"},{"key":"614_CR30","unstructured":"National Institute for Health and Care Excellence. Semaglutide for managing overweight and obesity. 2023 https:\/\/www.nice.org.uk\/guidance\/ta875"},{"key":"614_CR31","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"key":"614_CR32","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553\u201364. https:\/\/doi.org\/10.1111\/dom.14725.","journal-title":"Diabetes Obes Metab"},{"key":"614_CR33","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0.","journal-title":"Lancet"},{"key":"614_CR34","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403\u201313. https:\/\/doi.org\/10.1001\/jama.2021.1831.","journal-title":"JAMA"},{"key":"614_CR35","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414\u201325. https:\/\/doi.org\/10.1001\/jama.2021.3224.","journal-title":"JAMA"},{"key":"614_CR36","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u201391. https:\/\/doi.org\/10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"key":"614_CR37","doi-asserted-by":"publisher","first-page":"e13704","DOI":"10.1111\/obr.13704","volume":"25","author":"A Goldberg","year":"2024","unstructured":"Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, et al. Anti-obesity Pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024;25:e13704. https:\/\/doi.org\/10.1111\/obr.13704.","journal-title":"Obes Rev"},{"key":"614_CR38","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.3390\/jcm12185921","volume":"12","author":"E Carmina","year":"2023","unstructured":"Carmina E, Longo RA. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J Clin Med. 2023;12:5921. https:\/\/doi.org\/10.3390\/jcm12185921.","journal-title":"J Clin Med"},{"key":"614_CR39","doi-asserted-by":"publisher","first-page":"1366940","DOI":"10.3389\/fendo.2024.1366940","volume":"15","author":"M Jensterle","year":"2024","unstructured":"Jensterle M, Ferjan S, Janez A. The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study. Front Endocrinol (Lausanne). 2024;15:1366940. https:\/\/doi.org\/10.3389\/fendo.2024.1366940.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"614_CR40","doi-asserted-by":"publisher","first-page":"e009348","DOI":"10.1161\/CIRCOUTCOMES.122.009348","volume":"16","author":"J Hartmann-Boyce","year":"2023","unstructured":"Hartmann-Boyce J, Theodoulou A, Oke JL, Butler AR, Bastounis A, Dunnigan A, et al. Long-term effect of weight regain following behavioral weight management programs on cardiometabolic disease incidence and risk: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2023;16:e009348. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.122.009348.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"614_CR41","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cmet.2016.02.005","volume":"23","author":"F Magkos","year":"2016","unstructured":"Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23:591\u2013601. https:\/\/doi.org\/10.1016\/j.cmet.2016.02.005.","journal-title":"Cell Metab"},{"key":"614_CR42","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/humrep\/dew243","volume":"31","author":"S Cassar","year":"2016","unstructured":"Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31:2619\u201331. https:\/\/doi.org\/10.1093\/humrep\/dew243.","journal-title":"Hum Reprod"},{"key":"614_CR43","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/humrep\/des463","volume":"28","author":"NK Stepto","year":"2013","unstructured":"Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulinaemic clamp. Hum Reprod. 2013;28:777\u201384. https:\/\/doi.org\/10.1093\/humrep\/des463.","journal-title":"Hum Reprod"},{"key":"614_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","volume":"6","author":"DH Ryan","year":"2017","unstructured":"Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6:187\u201394. https:\/\/doi.org\/10.1007\/s13679-017-0262-y.","journal-title":"Curr Obes Rep"},{"key":"614_CR45","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","volume":"373","author":"G Whitlock","year":"2009","unstructured":"Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(09)60318-4.","journal-title":"Lancet"},{"key":"614_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12902-019-0434-8","volume":"19","author":"S Lim","year":"2019","unstructured":"Lim S, Smith CA, Costello MF, MacMillan F, Moran L, Ee C. Barriers and facilitators to weight management in overweight and obese women living in Australia with PCOS: a qualitative study. BMC Endocr Disord. 2019;19:106. https:\/\/doi.org\/10.1186\/s12902-019-0434-8.","journal-title":"BMC Endocr Disord"},{"key":"614_CR47","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1089\/jwh.2016.5792","volume":"26","author":"L Brennan","year":"2017","unstructured":"Brennan L, Teede H, Skouteris H, Linardon J, Hill B, Moran L. Lifestyle and behavioral management of polycystic ovary syndrome. J Womens Health (Larchmt). 2017;26:836\u201348. https:\/\/doi.org\/10.1089\/jwh.2016.5792.","journal-title":"J Womens Health (Larchmt)"},{"key":"614_CR48","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/jhrs.JHRS_95_18","volume":"13","author":"R Deswal","year":"2020","unstructured":"Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13:261\u201371. https:\/\/doi.org\/10.4103\/jhrs.JHRS_95_18.","journal-title":"J Hum Reprod Sci"},{"key":"614_CR49","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.fertnstert.2013.04.001","volume":"100","author":"SB Christensen","year":"2013","unstructured":"Christensen SB, Black MH, Smith N, Martinez MM, Jacobsen SJ, Porter AH, et al. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril. 2013;100:470\u20137. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.04.001.","journal-title":"Fertil Steril"},{"key":"614_CR50","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.3399\/bjgp18X695465","volume":"68","author":"A Cassell","year":"2018","unstructured":"Cassell A, Edwards D, Harshfield A, Rhodes K, Brimicombe J, Payne R, et al. The epidemiology of Multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2018;68:e245\u201351. https:\/\/doi.org\/10.3399\/bjgp18X695465.","journal-title":"Br J Gen Pract"},{"key":"614_CR51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12902-022-01208-y","volume":"23","author":"S Cowan","year":"2023","unstructured":"Cowan S, Lim S, Alycia C, Pirotta S, Thomson R, Gibson-Helm M, et al. Lifestyle management in polycystic ovary syndrome - beyond diet and physical activity. BMC Endocr Disord. 2023;23:14. https:\/\/doi.org\/10.1186\/s12902-022-01208-y.","journal-title":"BMC Endocr Disord"},{"key":"614_CR52","doi-asserted-by":"publisher","first-page":"204201882211271","DOI":"10.1177\/20420188221127142","volume":"13","author":"MA Abdalla","year":"2022","unstructured":"Abdalla MA, Shah N, Deshmukh H, Sahebkar A, Ostlundh L, Al-Rifai RH, et al. Impact of Metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. Ther Adv Endocrinol Metab. 2022;13:20420188221127142. https:\/\/doi.org\/10.1177\/20420188221127142.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"614_CR53","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1210\/jc.2004-2283","volume":"90","author":"LR Harborne","year":"2005","unstructured":"Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90:4593\u20138. https:\/\/doi.org\/10.1210\/jc.2004-2283.","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR54","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bmj.327.7421.951","volume":"327","author":"JM Lord","year":"2003","unstructured":"Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951\u20133. https:\/\/doi.org\/10.1136\/bmj.327.7421.951.","journal-title":"BMJ"},{"key":"614_CR55","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/s0029-7844(03)00045-0","volume":"101","author":"R Barbieri","year":"2003","unstructured":"Barbieri R. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol. 2003;101:785\u201393. https:\/\/doi.org\/10.1016\/s0029-7844(03)00045-0.","journal-title":"Obstet Gynecol"},{"key":"614_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13102-023-00653-z","volume":"15","author":"S Mohammadi","year":"2023","unstructured":"Mohammadi S, Monazzami A, Alavimilani S. Effects of eight-week high-intensity interval training on some metabolic, hormonal and cardiovascular indices in women with PCOS: a randomized controlled trial. BMC Sports Sci Med Rehabil. 2023;15:47. https:\/\/doi.org\/10.1186\/s13102-023-00653-z.","journal-title":"BMC Sports Sci Med Rehabil"},{"key":"614_CR57","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/nu8060354","volume":"8","author":"M Headland","year":"2016","unstructured":"Headland M, Clifton PM, Carter S, Keogh JB. Weight-loss outcomes: a systematic review and meta-analysis of intermittent energy restriction trials lasting a minimum of 6 months. Nutrients. 2016;8:354. https:\/\/doi.org\/10.3390\/nu8060354.","journal-title":"Nutrients"},{"key":"614_CR58","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1007\/s11695-023-06617-z","volume":"33","author":"P Luo","year":"2023","unstructured":"Luo P, Su Z, Li P, Wang G, Li W, Sun X, et al. Effects of sleeve gastrectomy on patients with obesity and polycystic ovary syndrome: a meta-analysis. Obes Surg. 2023;33:2335\u201341. https:\/\/doi.org\/10.1007\/s11695-023-06617-z.","journal-title":"Obes Surg"},{"key":"614_CR59","doi-asserted-by":"publisher","first-page":"1297841","DOI":"10.3389\/fendo.2024.1297841","volume":"15","author":"M Xie","year":"2024","unstructured":"Xie M, Yang Y, Zhang J. The effects of behavioral intervention on anthropometric, clinical, and biochemical parameters in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024;15:1297841. https:\/\/doi.org\/10.3389\/fendo.2024.1297841.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"614_CR60","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11154-023-09789-2","volume":"24","author":"P Shukla","year":"2023","unstructured":"Shukla P, Melkani GC. Mitochondrial epigenetic modifications and nuclear-mitochondrial communication: A new dimension towards Understanding and attenuating the pathogenesis in women with PCOS. Rev Endocr Metab Disord. 2023;24:317\u201326. https:\/\/doi.org\/10.1007\/s11154-023-09789-2.","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00614-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-025-00614-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00614-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:36:15Z","timestamp":1741221375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-025-00614-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1007\/s13679-025-00614-2","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"13 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"22"}}